Individualized toxicity‐titrated 6‐mercaptopurine increments during high‐dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia: A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study

Thomas L. Frandsen; Jonas Abrahamsson; Birgitte Lausen; Kim Vettenranta; Mats Heyman; Michael Behrentz; Anders Castor; Peder S. Wehner; Britt‐marie Frost; Elisabeth Wreford Andersen; Kjeld Schmiegelow

doi:10.1111/j.1365-2141.2011.08835.x

Individualized toxicity‐titrated 6‐mercaptopurine increments during high‐dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia: A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study

Thomas L. Frandsen, Jonas Abrahamsson, Birgitte Lausen, Kim Vettenranta, Mats Heyman, Michael Behrentz, Anders Castor, Peder S. Wehner, Britt‐marie Frost, Elisabeth Wreford Andersen, Kjeld Schmiegelow

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

This study explored the feasibility and toxicity of individualized toxicity‐titrated 6‐mercaptopurine (6MP) dose increments during post‐remission treatment with High‐dose methotrexate (HDM) (5000 mg/m2, ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m2 per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m2 per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity‐titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.

Original language	English
Journal	British Journal of Haematology
Volume	155
Issue number	2
Pages (from-to)	244-247
ISSN	0007-1048
DOIs	https://doi.org/10.1111/j.1365-2141.2011.08835.x
Publication status	Published - 2011
Externally published	Yes

Keywords

Acute lymphoblastic leukaemia
Chemotherapy
Children
Consolidation
Purine analogues

Access to Document

10.1111/j.1365-2141.2011.08835.x

Fingerprint Dive into the research topics of 'Individualized toxicity‐titrated 6‐mercaptopurine increments during high‐dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia: A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study'. Together they form a unique fingerprint.

Cite this

Frandsen, T. L., Abrahamsson, J., Lausen, B., Vettenranta, K., Heyman, M., Behrentz, M., Castor, A., Wehner, P. S., Frost, B., Andersen, E. W., & Schmiegelow, K. (2011). Individualized toxicity‐titrated 6‐mercaptopurine increments during high‐dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia: A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. British Journal of Haematology, 155(2), 244-247. https://doi.org/10.1111/j.1365-2141.2011.08835.x

Frandsen, Thomas L. ; Abrahamsson, Jonas ; Lausen, Birgitte ; Vettenranta, Kim ; Heyman, Mats ; Behrentz, Michael ; Castor, Anders ; Wehner, Peder S. ; Frost, Britt‐marie ; Andersen, Elisabeth Wreford ; Schmiegelow, Kjeld. / Individualized toxicity‐titrated 6‐mercaptopurine increments during high‐dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia : A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. In: British Journal of Haematology. 2011 ; Vol. 155, No. 2. pp. 244-247.

@article{6cdb83d7a59b4461816e2308766866ad,

title = "Individualized toxicity‐titrated 6‐mercaptopurine increments during high‐dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia: A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study",

abstract = "This study explored the feasibility and toxicity of individualized toxicity‐titrated 6‐mercaptopurine (6MP) dose increments during post‐remission treatment with High‐dose methotrexate (HDM) (5000 mg/m2, ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m2 per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m2 per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity‐titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.",

keywords = "Acute lymphoblastic leukaemia, Chemotherapy, Children, Consolidation, Purine analogues",

author = "Frandsen, {Thomas L.} and Jonas Abrahamsson and Birgitte Lausen and Kim Vettenranta and Mats Heyman and Michael Behrentz and Anders Castor and Wehner, {Peder S.} and Britt‐marie Frost and Andersen, {Elisabeth Wreford} and Kjeld Schmiegelow",

year = "2011",

doi = "10.1111/j.1365-2141.2011.08835.x",

language = "English",

volume = "155",

pages = "244--247",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "2",

}

Frandsen, TL, Abrahamsson, J, Lausen, B, Vettenranta, K, Heyman, M, Behrentz, M, Castor, A, Wehner, PS, Frost, B, Andersen, EW & Schmiegelow, K 2011, 'Individualized toxicity‐titrated 6‐mercaptopurine increments during high‐dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia: A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study', British Journal of Haematology, vol. 155, no. 2, pp. 244-247. https://doi.org/10.1111/j.1365-2141.2011.08835.x

Individualized toxicity‐titrated 6‐mercaptopurine increments during high‐dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia : A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. / Frandsen, Thomas L.; Abrahamsson, Jonas; Lausen, Birgitte; Vettenranta, Kim; Heyman, Mats; Behrentz, Michael; Castor, Anders; Wehner, Peder S.; Frost, Britt‐marie; Andersen, Elisabeth Wreford; Schmiegelow, Kjeld.

In: British Journal of Haematology, Vol. 155, No. 2, 2011, p. 244-247.

Research output: Contribution to journal › Journal article › Research › peer-review

TY - JOUR

T1 - Individualized toxicity‐titrated 6‐mercaptopurine increments during high‐dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia

T2 - A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study

AU - Frandsen, Thomas L.

AU - Abrahamsson, Jonas

AU - Lausen, Birgitte

AU - Vettenranta, Kim

AU - Heyman, Mats

AU - Behrentz, Michael

AU - Castor, Anders

AU - Wehner, Peder S.

AU - Frost, Britt‐marie

AU - Andersen, Elisabeth Wreford

AU - Schmiegelow, Kjeld

PY - 2011

Y1 - 2011

N2 - This study explored the feasibility and toxicity of individualized toxicity‐titrated 6‐mercaptopurine (6MP) dose increments during post‐remission treatment with High‐dose methotrexate (HDM) (5000 mg/m2, ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m2 per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m2 per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity‐titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.

AB - This study explored the feasibility and toxicity of individualized toxicity‐titrated 6‐mercaptopurine (6MP) dose increments during post‐remission treatment with High‐dose methotrexate (HDM) (5000 mg/m2, ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m2 per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m2 per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity‐titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.

KW - Acute lymphoblastic leukaemia

KW - Chemotherapy

KW - Children

KW - Consolidation

KW - Purine analogues

U2 - 10.1111/j.1365-2141.2011.08835.x

DO - 10.1111/j.1365-2141.2011.08835.x

M3 - Journal article

C2 - 21848519

VL - 155

SP - 244

EP - 247

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -

Frandsen TL, Abrahamsson J, Lausen B, Vettenranta K, Heyman M, Behrentz M et al. Individualized toxicity‐titrated 6‐mercaptopurine increments during high‐dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia: A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. British Journal of Haematology. 2011;155(2):244-247. https://doi.org/10.1111/j.1365-2141.2011.08835.x